Shares of UiPath Inc. (NYSE:PATH – Get Free Report) have been given an average rating of “Hold” by the fourteen research firms that are presently covering the stock, MarketBeat reports. Eight equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $18.91.
Several analysts have recently weighed in on the company. Barclays decreased their target price on UiPath from $17.00 to $16.00 in a research report on Thursday, May 25th. BMO Capital Markets cut their target price on UiPath from $20.00 to $18.00 in a research note on Thursday, May 25th. Wells Fargo & Company lowered UiPath from an “overweight” rating to an “equal weight” rating and set a $20.00 target price on the stock. in a research note on Friday, June 9th. Finally, DA Davidson initiated coverage on UiPath in a research note on Thursday, April 20th. They issued a “neutral” rating and a $16.00 target price on the stock.
UiPath Trading Down 7.7 %
NYSE:PATH opened at $16.42 on Thursday. UiPath has a twelve month low of $10.40 and a twelve month high of $22.19. The company has a market cap of $9.21 billion, a price-to-earnings ratio of -38.17 and a beta of 0.67. The stock has a fifty day simple moving average of $17.32 and a 200-day simple moving average of $16.06.
UiPath (NYSE:PATH – Get Free Report) last released its earnings results on Wednesday, May 24th. The healthcare company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.08. UiPath had a negative return on equity of 10.07% and a negative net margin of 21.55%. The business had revenue of $289.59 million during the quarter, compared to the consensus estimate of $271.25 million. As a group, equities research analysts predict that UiPath will post -0.26 EPS for the current fiscal year.
Insider Buying and Selling at UiPath
In other UiPath news, CAO Hitesh Ramani sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, May 26th. The stock was sold at an average price of $15.56, for a total value of $155,600.00. Following the completion of the transaction, the chief accounting officer now directly owns 433,371 shares of the company’s stock, valued at $6,743,252.76. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other UiPath news, CFO Ashim Gupta sold 40,000 shares of the company’s stock in a transaction on Monday, July 17th. The stock was sold at an average price of $18.44, for a total value of $737,600.00. Following the completion of the sale, the chief financial officer now directly owns 1,384,047 shares in the company, valued at approximately $25,521,826.68. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CAO Hitesh Ramani sold 10,000 shares of the company’s stock in a transaction on Friday, May 26th. The shares were sold at an average price of $15.56, for a total value of $155,600.00. Following the completion of the transaction, the chief accounting officer now directly owns 433,371 shares in the company, valued at approximately $6,743,252.76. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 242,546 shares of company stock valued at $4,273,742. 31.03% of the stock is owned by company insiders.
Hedge Funds Weigh In On UiPath
Several large investors have recently modified their holdings of PATH. Raymond James Financial Services Advisors Inc. lifted its stake in shares of UiPath by 3.8% in the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 40,993 shares of the healthcare company’s stock valued at $885,000 after purchasing an additional 1,506 shares during the last quarter. MetLife Investment Management LLC acquired a new position in UiPath during the 1st quarter worth about $184,000. BlackRock Inc. lifted its stake in UiPath by 1.9% during the 1st quarter. BlackRock Inc. now owns 5,316,635 shares of the healthcare company’s stock worth $114,786,000 after acquiring an additional 99,242 shares in the last quarter. Dimensional Fund Advisors LP acquired a new position in UiPath during the 1st quarter worth about $534,000. Finally, Canada Pension Plan Investment Board acquired a new position in UiPath during the 1st quarter worth about $259,000. Institutional investors and hedge funds own 56.91% of the company’s stock.
About UiPath
UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.